DOCSLIB.ORG

Col11bined Index to USP 37 and NF 32, Volul11es 1-4

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

..... Combined Index to USP 37 and NF 32 Abaca-Aceto 1-1 COl11bined Index to USP 37 and NF 32, Volul11es 1-4 Page citations refer to the pages of Volumes 7, 2, 3, and 4 of uSP 37-NF 32. This index is repeated in its entirety in each volume. 1-1554 Volume 1 1555-3460 Volume 2 3461-5230 Volume 3 5231-6262 Volume 4 Numbers in angle brackets such as (421) refer to chapter numbers in the General Chapters section. and (salts of) chlorpheniramine, isometheptene mucate, and dextromethorphan, and dichloralphenazone capsules, 3416 phenylpropanolamine, oral solution and oxycodone capsules, 4141 Abacavir containing at least three of the and oxycodone tablets, 4142 oral solution, 1S5 5 following, 1576 and pentazocine tablets, 4231 sulfate, 1556 and (salts of) chlorpheniramine, and propoxyphene hydrochloride tablets, tablets, 1557 dextromethorphan, and 4458 Absolute phenylpropanolamine, tablets containing and propoxyphene napsylate tablets, 4463 alcohol, 1373 at least three of the following, 1577 and pseudoephedrine hydrochloride ether, 1372 and (salts of) chlorpheniramine, tablets, 1597 Absorbable dextromethorphan, and oral solution, 1566 dusting powder, 2745 pseudoephedrine, capsules containing at for effervescent oral solution, 1567 gelatin film, 3132 least three of the following, 1579 suppositories, 1567 gelatin sponge, 3132 and (salts of) chlorpheniramine, oral suspension, 1568 surgical suture, 4808 dextromethorphan, and tablets, 1569 Absorbent pseudoephedrine, oral powder extended-release tablets, 1570 cotton, 1372 containing at least three of the and tramadol hydrochloride oral gauze, 3131 following, 1582 suspension, 5015 odorless paper, 141 3 and (salts of) chlorpheniramine, and tramadol hydrochloride tablets, 1598 Acacia, 5831 dextromethorphan, and Acetanilide, 1372 syrup, 5831 pseudoephedrine, oral solution Acetate, methyl, 1408 Acarbose, 1559 containing at least three of the Acetate buffer, 1443 Acebutolol hydrochloride, 1560 following, 1584 T5, 1445 capsules, 1561 and (salts of) chlorpheniramine, Acetazolamide, 1600 Acepromazine maleate, 1562 dextromethorphan, and for injection, 1601 injection, 1563 pseudoephedrine, tablets containing at oral suspension, 1601 tablets, 1563 least three of the following, 1586 tablets, 1602 Acesulfame potassium, 5832 chlorpheniramine maleate, and Acetic acid, 1372, 5833 Acetal, 1372 dextromethorphan hydrobromide ammonium acet.,te buffer T5, 1445 Acetaldehyde, 1372 tablets, 1588 diluted, 1372, 5833 T5, 1445 and codeine phosphate capsules, 1589 double-normal (2 N), 1454 Acetaminophen, 1564 and codeine phosphate oral solution, 1590 glacial, 1372, 1603 aspirin and caffeine tablets, 1572 and codeine phosphate oral suspension, glacial, T5, 1445 and aspirin tablets, 1571 1591 and hydrocortisone otic solution, 3258 butalbital and caffeine capsules, 2043 and codeine phosphate tablets, 1592 irrigation, 1603 butalbital and caffeine tablets, 2044 dextromethorphan hydrobromide, metaphosphoric, T5, 1450 and caffeine tablets, 1573 doxylamine succinate, and otic solution, 1604 capsules, 1566 pseudoephedrine hydrochloride oral strong, T5, 1445 and (salts of) chlorpheniramine, solution, 1593 Acetic acid in peptides, 229 dextromethorphan, and and diphenhydramine citrate tablets, 1595 Acetic anhydride, 1372 phenylpropanolamine, capsules diphenhydramine hydrochloride, and Acetohexamide, 1604 containing at least three of the pseudoephedrine hydrochloride tablets, tablets, 1604 following, 1574 1596 Acetohydroxamic acid, 1605 and hydrocodone bitartrate tablets, 3250 tablets, 1606 1-2 Aceto-Aluml Combined Index to USP 37 and NF 32 Can Acetone, 1372, 5834 Benzocaine topical, 1933 Alcoholic AlulT anhydrous, 1372 Betamethasone dipropionate topical, 1962 ammonia TS, 1446 as! neutralized, 1372, 1445 Dexamethasone sodium phosphate mercuric bromide TS, 1446 Acetonitrile, 1372 inhalation, 2550 potassium hydroxide TS, 1446 spectrophotometric, 1372 Dexamethasone topical, 2543 potassium hydroxide TS 2, 1451 Acetophenone, 1372 Epinephrine bitartrate inhalation, 2809 TS,1446 p-Acetotoluidide, 1372 Epinephrine inhalation, 2806 Alcoholometric table, 1549 Acetylacetone, 1372 Ergotamine tartrate inhalation, 2827 Aldehyde dehydrogenase, 1374 m Acetyl chloride, 1372 Fluticasone propionate inhalation, 3062 Alendronate sodium, 1638 Acetylcholine chloride, 1372, 1607 Isoetharine mesylate inhalation, 3409 tablets, 1640 m for ophthalmic solution, 1607 Isoproterenol hydrochloride inhalation, Alfadex, 5841 Acetylcysteine, 1608 3424 Alfentanil m and isoproterenol hydrochloride inhalation Isoproterenol hydrochloride and hydrochloride, 1641 solution, 1609 phenylephrine bitartrate inhalation, 3426 injection, 1642 ar solution, 1609 Isoproterenol sulfate inhalation, 3428 Alfuzosin hydrochloride, 1643 ar N-Acetylglucosamine, 5231 Lidocaine topical, 3551 extended-release tablets, 1644 m 3-Acetylthio-2-methylpropanoic acid, 1373 Metaproterenol sulfate inhalation, 3726 Alginates assay (311), 178 Acetyltributyl citrate, 5835 Polymyxin B sulfate and bacitracin zinc Alginic acid, 5842 ar Acetyltriethyl citrate, 5835 topical, 4338 Alizarin complexone, 1374 N-Acetyltyrosine, 5232 Povidone-iodine topical, 4373 Alkaline ar N-Acetyl-L-tyrosine ethyl ester, 1373 Terbutaline sulfate inhalation, 4881 borate buffer, 1443 ar Acid Thimerosal topical, 4931 cupric citrate TS, 1446 acrylic, 1373 Tolnaftate topical, 4999 cupric citrate TS 2, 1446 ar alpha lipoic, 5467 Triamcinolone acetonide topical, 5033 cupric iodide TS, 1446 Alur dehydroacetic, 5957 cupric tartrate TS, 1446 Alur ferric chloride TS, 1445 mercuric-potassium iodide TS, 1446 al ferrous sulfate TS, 1445 phosphatase enzyme, 1374 d phthalate buffer, 1443 Agar, 1373, 5837 picrate TS, 1446 d stannous chloride TS, 1445 Agarose, 1373 pyrogallol TS, 1451 d stannous chloride TS, stronger, 1445 Air, medical, 1624 sodium hydrosulfite TS, 1446 d Acid-neutralizing capacity (301), 177 Air-helium certified standard, 1373 Alkyl (C12-15) benzoate, 5843 d Alanine, 1625 Acidulated phosphate and sodium fluoride Alkylphenoxypolyethoxyethanol, 1374 di topical solution, 4716 Albendazole, 1625 Allantoin, 1648 di oral suspension, 1626 Acitretin, 161 0 Allopurinol, 1649 d tablets, 1626 capsules, 1612 oral suspension, 1651 d Acoustic emission (1005), 511 Albumen TS, 1446 tablets, 1651 h Albumin Acrylic acid, 1373 Allyl isothiocyanate, 1652 h bovine serum, 1373 Activated Almond oil, 5843 h human, 1627 alumina, 1373 Aloe, 1652 h rAlbumin, 5838 charcoal, 1373, 2274 Alpha IT magnesium silicate, 1373 Albuterol, 1628 lipoic acid, 5467 o Acyclovir, 161 3 sulfate, 1628 tocopherol assay (551), 237 o tablets, 1629 capsules, 1614 Alpha-chymotrypsin, 1374 p for injection, 1614 Alclometasone dipropionate, 1630 Alpha cyclodextrin hydrate, 1374 cream, 1631 P ointment, 1616 Alpha-(2-(methylamino)ethyl)benzyl alcohol, S4 ointment, 1632 oral suspension, 161 6 1374 Sl Alcohol, 1373, 1633 tablets, 161 7 Alphanaphthol, 1374 Sl Adamantane, 1373 70 percent, 80 percent, and 90 percent, Alphazurine 2G, 1441 1373 Adapalene, 1618 Alprazolam, 1654 Sl absolute, 1373 Ademetionine disulfate tosylate, 5535 oral suspension, 1655 Sl aldehyde-free, 1373 Adenine, 1620 tablets, 1655 Sl alpha-(2-(methylamino)ethyl)benzyl, 1374 sulfate, 1373 extended-release tablets, 1657 Sl Adenosine, 1621 amyl, 1373 orally disintegrating tablets, 1659 injection, 1623 tert-amyl, 1377 Alprenolol hydrochloride, 1374 z Adipic acid, 1373, 5836 butyl,5878 Alprostadil, 1661 z Admissions dehydrated, 1373, 1635 injection, 1663 to NF 32,5819 dehydrated isopropyl, 1373 Alteplase, 1664 • z to USP 37, xxxvii denaturated, 1373 for injection, 1667 z Advisory Groups, xxiii denaturated, TS, 1447 Alternative microbiological sampling methods determination (611), 296 for nonsterile inhaled and nasal products z in dextrose injection, 1637 (610), 295 z diluted, 1374, 5840 Altretamine, 1668 Aerosol injection, dehydrated, 1636 capsules, 1668 z isobutyl, 1374 Alum, 1374 z Aerosols, nasal sprays, metered-dose isopropyl, 1374 ammonium, 1374, 1669 inhalers, and dry powder inhalers (601), methyl, 1374 potassium, 1418, 1669 273 neutralized, 1374 Alumina, 1374 Bacitracin and polymyxin B sulfate topical, phenol TS, 1446 activated, 1374 n-propyl, 1374 1905 anhydrous, 1374 2 Benzocaine, butamben, and tetracaine rubbing, 1638 aspirin, codeine phosphate, and magnesia • 2 hydrochloride topical, 1936 secondary butyl, 1374 tablets, 1854 Benzocaine and menthol topical, 1939 tertiary butyl, 1374 aspirin, and magnesia tablets, 1847 • Combined Index to USP 37 and NF 32 Aluml-Ammon 1-3 Alumina (continued) zirconium trichlorohydrate solution, 1710 Aminophylline, 1739 aspirin, and magnesium oxide tablets, zirconium trichlorohydrex gly, 1711 injection, 1740 1848 zirconium trichlorohydrex gly solution, oral solution, 1741 magnesia, and calcium carbonate 1712 rectal solution, 1741 chewable tablets, 1673 Aluminum (206), 145 suppositories, 1742 magnesia, calcium carbonate, and Amantadine hydrochloride, 1713 tablets, 1743 simethicone chewable tablets, 1674 capsules, 1714 delayed-release tablets, 1744 magnesia, and calcium carbonate oral oral solution, 1715 3-Aminopropionic acid, 1376 suspension, 1672 Amaranth, 1375 Aminosalicylate sodium, 1745 magnesia, and simethicone chewable TS, 1446 tablets, 1746 tablets, 1678 Amcinonide, 1716 Aminosalicylic acid, 1747 magnesia, and simethicone oral cream, 1716 tablets, 1749 suspension, 1676 ointment, 1717 3-Aminosalicylic acid, 1376 and magnesia oral suspension, 1670 American ginseng, 5233 3-Amino-1-propanol, 1376 and magnesia tablets, 1671 capsules, 5237 Amiodarone hydrochloride, 1750 magnesium
Recommended publications
  • Additions and Deletions to the Drug Product List

    Additions and Deletions to the Drug Product List

    Prescription and Over-the-Counter Drug Product List 40TH EDITION Cumulative Supplement Number 09 : September 2020 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; BUTALBITAL; CAFFEINE TABLET;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE >A> AA STRIDES PHARMA 325MG;50MG;40MG A 203647 001 Sep 21, 2020 Sep NEWA ACETAMINOPHEN; CODEINE PHOSPHATE SOLUTION;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >D> AA WOCKHARDT BIO AG 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC >A> @ 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC TABLET;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >A> AA NOSTRUM LABS INC 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >A> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >A> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN >D> AA TEVA 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >D> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >D> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET;ORAL HYDROCODONE BITARTRATE AND ACETAMINOPHEN >A> @ CEROVENE INC 325MG;5MG A 211690 001 Feb 07, 2020 Sep CAHN >A> @ 325MG;7.5MG A 211690 002 Feb 07, 2020 Sep CAHN >A> @ 325MG;10MG A 211690 003 Feb 07, 2020 Sep CAHN >D> AA VINTAGE PHARMS 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >A> @ 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >D> AA 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >A> @ 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >D> AA 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >A> @ 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >D> @ XIROMED 325MG;5MG A 211690
  • Neonatal Intensive Care Drug Therapy Update: a Bibliography

    Neonatal Intensive Care Drug Therapy Update: a Bibliography

    LWW/JPNN AS310-13 July 28, 2004 23:11 Char Count= 0 J Perinat Neonat Nurs Vol. 18, No. 3, pp. 292–306 c 2004 Lippincott Williams & Wilkins, Inc. Neonatal Intensive Care Drug Therapy Update: A Bibliography Jason Sauberan, PharmD BIBLIOGRAPHY I. Overview A. Clark RH, Bloom BT, Gerstmann DR Medications Used in Neonatal Intensive Care Units—A Descriptive Study [abstract 3047]. In: Program and abstracts of the 2004 Pediatric Academic Societies’ Annual Meeting, San Francisco, CA. B. Barr J, Brenner-Zada G, Heiman E, Pareth G, Bulkowstein M, Greenberg R, Berkovitch M. Unlicensed and off-label medication use in a neonatal intensive care unit: a prospective study. Am J Perinatol. 2002 Feb;19(2):67–72. C. O’Donnell CP, Stone RJ, Morley CJ. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics. 2002 Nov;110(5):e52. D. Committee on Drugs. American Academy of Pediatrics. Uses of drugs not described in the package insert (off-label uses). Pediatrics. 2002 Jul;110(1 Pt 1):181–3. II. Anti-infectives A. Linezolid 1. Deville JG, Adler S, Azimi PH, Jantausch BA, Morfin MR, Beltran S, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr Infect Dis J. 2003 Sep;22(9 Suppl):S158–63. 2. Vo M, Cirincione BB, Rubino CM, Jungbluth GL. Pharmacokinetics of Linezolid in Neonates and Young Infants [abstract A-1409]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA.
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0129775 A1 Lanphere Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2005/0129775 A1 Lanphere Et Al

    US 2005O129775A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0129775 A1 Lanphere et al. (43) Pub. Date: Jun. 16, 2005 (54) FERROMAGNETIC PARTICLES AND (22) Filed: Aug. 27, 2004 METHODS Related U.S. Application Data (75) Inventors: Janel Lanphere, Pawtucket, RI (US); Erin McKenna, Boston, MA (US); (63) Continuation-in-part of application No. 10/651,475, Thomas V. Casey II, Grafton, MA filed on Aug. 29, 2003. (US) Publication Classification Correspondence Address: FISH & RICHARDSON PC (51) Int. Cl." ........................... A61K 9/127; A61K 9/14; 225 FRANKLIN ST A61K 33/26 BOSTON, MA 02110 (US) (52) U.S. Cl. ............................................ 424/489; 424/646 (73) ASSignee: Siedle Systems, Inc., Maple (57) ABSTRACT (21) Appl. No.: 10/928,452 Ferromagnetic particles and methods are disclosed. Patent Application Publication Jun. 16, 2005 Sheet 1 of 5 US 2005/0129775 A1 Patent Application Publication Jun. 16, 2005 Sheet 2 of 5 US 2005/0129775 A1 s nS) l r N. 1 Yn ESDNIAJ?SdWßd N-EZT| 1 - - - - - - - - - - - - - - - - - - - - - - - - - a - - a - - - - Patent Application Publication Jun. 16, 2005 Sheet 3 of 5 US 2005/0129775 A1 : 3 L D Cl U c). Z Y X C) Patent Application Publication Jun. 16, 2005 Sheet 4 of 5 US 2005/0129775 A1 s s Patent Application Publication Jun. 16, 2005 Sheet 5 of 5 US 2005/0129775 A1 26SS EMBOLIC PARTICLES FIBROID jS. 111 UTERINE ARTERY CATHETER 150 FIG. R., US 2005/0129775 A1 Jun. 16, 2005 FERROMAGNETIC PARTICLES AND METHODS 0011 Heating a particle can include exposing the particle to RF radiation. CROSS-REFERENCE TO RELATED 0012.
  • Application and Review of Pediatric Pharmacotherapy, Sample Chapter

    Application and Review of Pediatric Pharmacotherapy, Sample Chapter

    Application and Review of Pediatric Pharmacotherapy Chapter No. 1 Dated: 29/7/2010 At Time: 16:16:4 Section 1 Neonatal intensive care “Luck is where preparation meets opportunity.” This section consists of 16 medication orders followed by corresponding patient profiles representing pharmacotherapy associated with patients admit- ted to a neonatal intensive care unit. Each patient profile is followed by multiple-choice questions pertaining to the medication order and profile infor- mation. Choose the one best-lettered response to each item. The correct answers are provided at the end of this section. The reader is encouraged to attempt all questions for each case or for the entire section prior to referring to the answers. Moreover, where appropriate, the answer key provides a thor- ough explanation of the correct response and should serve as an additional learning tool for the reader. Application and Review of Pediatric Pharmacotherapy Chapter No. 1 Dated: 29/7/2010 At Time: 16:16:4 2 | Application and Review of Pediatric Pharmacotherapy Medication orders Physician order Patient weight: 2.5 kg Aminophylline 10 mg iv load, then begin 2.5 mg iv q 12 h Obtain theophylline concentration 1 h postinfusion of loading dose Date/time: 12/01/2100 Patient name: Baby Boy Turner Physician: John Craver Patient ID: 111222 Medical profile Patient: Baby Boy Turner Patient weight: 2.5 kg Age: 1d/o Present illness: Apneic episodes Allergies: None Medical history: 33 weeks gestation, Apgar 7 and 9 Labs: pending Medication profile Questions Q1 Which of the following is an acceptable definition of apnea of prematurity? 1 o cessation of breathing for less than 20 s 2 o cessation of breathing for at least 20 s 3 o cessation of breathing for less than 20 s when accompanied by bradycardia A o 1 only B o 3 only C o 1 and 3 only Application and Review of Pediatric Pharmacotherapy Chapter No.
  • Caffeine in the Treatment of Pain

    Caffeine in the Treatment of Pain

    Rev Bras Anestesiol ARTIGOS DE REVISÃO 2012; 62: 3: 387-401 ARTIGOS DE REVISÃO Cafeína para o Tratamento de Dor Cristiane Tavares, TSA 1, Rioko Kimiko Sakata, TSA 2 Resumo: Tavares C, Sakata RK – Cafeína para o Tratamento de Dor. Justificativa e objetivos: A cafeína é uma substância amplamente consumida com efeitos em diversos sistemas e que apresenta farmacoci- nética e farmacodinâmica características, causando interações com diversos medicamentos. O objetivo deste estudo é fazer uma revisão sobre os efeitos da cafeína. Conteúdo: Nesta revisão, são abordados a farmacologia da cafeína, os mecanismos de ação, as indicações, as contraindicações, as doses, as interações e os efeitos adversos. Conclusões: Faltam estudos controlados, randomizados e duplos-cegos para avaliar a eficácia analgésica da cafeína nas diversas síndromes dolorosas. Em pacientes com dor crônica, é necessário ter cautela em relação ao desenvolvimento de tolerância, abstinência e interação medi- camentosa no uso crônico de cafeína. Unitermos: ANALGESIA; DOR; DROGAS, Alcaloide/cafeína. ©2012 Elsevier Editora Ltda. Todos os direitos reservados. INTRODUÇÃO Estrutura química A cafeína foi isolada em 1820, mas a estrutura correta des- A cafeína é um alcaloide presente em mais de 60 espécies ta metilxantina foi estabelecida na última década do século de plantas 4. Sua estrutura molecular pertence a um grupo XIX. Os efeitos não foram claramente reconhecidos até 1981, de xantinas trimetiladas que incluem seus compostos inti- quando o bloqueio de receptores adenosina foi correlacio- mamente relacionados: teobromina (presente no cacau) e nado às propriedades estimulantes da cafeína e de seus teofilina (presente no chá) 1. Quimicamente, esses alcaloides análogos 1. Provavelmente a cafeína é uma das substâncias são semelhantes a purinas, xantinas e ácido úrico, que são psicoativas mais utilizadas no mundo, promovendo efeitos compostos metabolicamente importantes 4.
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
  • Chemistry Inventory; Fall

    Chemistry Inventory; Fall

    CHEMISTRY FALL 2005 MSDS Mfg.'s Name Chemical Name Quantity Stored Storage Conditions (on file = 9) Aluminum 9 1.5 kg Aluminum chloride, anhydrous, 98.5% 9 0.2 kg Aluminum chloride · 6H2O 9 0.5 kg Aluminum hydroxide 9 0.5 kg Aluminum nitrate 9 0.5 kg Aluminum sulfate 9 0.5 kg Ammonia, concentrated 9 4.0 L Ammonium acetate 9 0.2 kg Ammonium chloride 9 Ammonium dihydrogen phosphate (monobasic) 9 0.4 kg J.T. Baker Ammonium hydrogen phosphate (dibasic) No 0.5 kg Ammonium nitrate 9 2.5 kg Ammonium oxalate 9 0.7 kg Ammonium peroxydisulfate 9 0.5 kg Ammonium sulfate 9 0.2 kg Antimony 9 0.4 kg Barium chloride, anhydrous 9 2.5 kg Barium chloride · 2H2O 9 2.5 kg Barium nitrate 9 0.8 kg Bismuth 9 2.0 kg Boric Acid 9 0.4 kg Brass 9 Bromine 9 2.5 kg Cadmium 9 0.1 kg Cadmium nitrate 9 0.3 kg Calcium acetate · xH2O 9 0.5 kg Calcium carbide 9 1.0 kg Calcium carbonate 9 2.2 kg Calcium chloride 9 1.0 kg Calcium hydroxide 9 0.3 kg Calcium nitrate · 4H2O 9 1.0 kg Calcium oxide 9 0.3 kg Calcium sulfate · 2H2O 9 1.0 kg Carbon 9 0.1 kg Ceric ammonium nitrate 9 0.5 kg Cesium chloride 9 0.01 kg Chromium 9 0.01 kg Chromium chloride 9 0.5 kg Chromium nitrate 9 0.5 kg Cobalt 9 0.025 kg Cobalt chloride 9 0.7 kg Cobalt nitrate 9 0.6 kg Copper (assorted) 9 4.0 kg Copper acetate 9 0.05 kg Copper chloride 9 0.1 kg Copper nitrate 9 3.5 kg Copper oxide 9 0.4 kg Cupric sulfate, anhydrous 9 0.5 kg Cupric sulfate · 5H2O 9 2.75 kg EDTA 9 0.6 kg Iodine 9 2.0 kg Iron (assorted) 9 5.0 kg MSDS Mfg.'s Name Chemical Name Quantity Stored Storage Conditions (on file = 9) Ferric ammonium
  • Caffeine Citrate 10Mg/Ml Oral Solution Maintenance Doses

    Caffeine Citrate 10Mg/Ml Oral Solution Maintenance Doses

    PACKAGE LEAFLET: INFORMATION FOR THE PATIENT doctor or nurse may give one more higher • changes in blood tests (reduced levels dose, before continuing to the lower of haemoglobin after prolonged Caffeine Citrate 10mg/ml Oral Solution maintenance doses. treatment) Duration of treatment • reduced thyroid hormone at the start Equivalent to Caffeine 5mg/ml Your baby’s doctor will decide exactly of treatment with other medicines given at the same Please read all of this leaflet carefully how long your newborn must continue Reporting of side effects time. A premature baby may need many before your baby is given this therapy with Caffeine Citrate 10mg/ml If your newborn gets any side effects, medicines, and any problems with caffeine medicine. Oral Solution. If your baby has 5 to 7 days talk to your baby’s doctor. This includes are likely to be minor, but tell the doctor • Keep this leaflet. You may need to read without apnoea attacks, the doctor will any possible side effects not listed in this about any other medication they may it again. stop treatment. leaflet. You can also report side effects D04359 not know about, particularly any other • If you have further questions, please The doctor may decide to check the directly via Yellow Card Scheme. medicine (for example theophylline) given ask the hospital doctor who is looking levels of caffeine in a blood sample Website: www.mhra.gov.uk/yellowcard to your baby to help it breathe. after your baby. as a precaution, or if your baby is not or search for MHRA Yellow Card in the If your newborn gets any side effects, Medications containing phenobarbitone responding to treatment as expected.
  • Nevada Medicaid Formulary

    Nevada Medicaid Formulary

    Nevada Medicaid-Approved Preferred Drug List Effective August 15, 2021 Legend In each class, drugs are listed alphabetically by either brand name or generic name. Brand name drug: Uppercase in bold type Generic drug: Lowercase in plain type AL: Age Limit Restrictions DO: Dose Optimization Program GR: Gender Restriction OTC: Over the counter medication available with a prescription. (Prescribers please indicate OTC on the prescription) PA: Prior authorization is required. Prior authorization is the process of obtaining approval of benefits before certain prescriptions are filled. QL: Quantity limits; certain prescription medications have specific quantity limits per prescription or per month. SP: Specialty Pharmacy ST: Step therapy is required. You may need to use one medication before benefits for the use of another medication can be authorized. Drug Name Reference Notes *ADHD/ANTI-NARCOLEPSY/ANTI- OBESITY/ANOREXIANTS* *ADHD AGENT - SELECTIVE ALPHA ADRENERGIC AGONISTS*** clonidine hcl er oral tablet extended release Kapvay AL; QL 12 hour *ADHD AGENT - SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR*** atomoxetine hcl oral capsule Strattera DO; AL; QL *AMPHETAMINE MIXTURES*** amphetamine-dextroamphet er oral capsule extended release 24 hour 10 mg, 15 mg, 5 Adderall XR DO; AL; QL mg amphetamine-dextroamphet er oral capsule extended release 24 hour 20 mg, 25 mg, 30 Adderall XR AL; QL mg amphetamine-dextroamphetamine oral Adderall DO; AL; QL tablet 10 mg, 12.5 mg, 15 mg, 5 mg, 7.5 mg amphetamine-dextroamphetamine oral Adderall AL tablet 20 mg,
  • Supplement 12

    Supplement 12

    APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS 14TH EDITION Cumulative Supplement 1 2 DECEMBER 1994 CONTENTS PAGE 1.0 INTRODUCTION............................................. iii 1.1 Ilow to Use the Cumulative Supplement .. iii 1.2 Products Requiring Revised Labeling for Full Approval . v 1.3 Applicant Name Changes. vi 1.4 New Indications for Previously Approved Drug Products ............... vii 1 .5 USP Monograph Title Additions or Changes . ix 1.6 Report of Counts for the Prescription Drug Product List. x 2.0 DRUG PRODUCT LISTS ....................................... 2.1 Prescription Drug Product List ................................. 1 2.2 OTC Drug Product List ...................................... 61 2.3 Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List. 63 2.4 Orphan Drug Product Designations . 64 2.5 Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution ................ 70 2.6 Biopharmaceutic Guidance Availability ........................... 71 2.7 ANDA Suitability Petitions . 72 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM A. Exclusivity Terms. 74 B. Patent and Exclusivity Lists . 76 APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS 14TH EDITION CUMULATIVE SUPPLEMENT 12 DECEMBER 1994 1.0 INTRODUCTION 1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence
  • LGC Standards Pharmacopoeial Reference Standards 2014

    LGC Standards Pharmacopoeial Reference Standards 2014

    LL CTS INKSP RODUTO A L P ITH W WEBSHO LGC Standards Pharmacopoeial reference standards 2014 FOR STANDARDS WITH CofA SEE OUR CATALOGUE: PHARMACEUTICAL IMPURITIES AND PRIMARY REFERENCE STANDARDS LGC Quality – ISO Guide 34 • GMP/GLP • ISO 9001 • ISO/IEC 17025 • ISO/IEC 17043 Pharmaceutical impurities Code Product CAS No. CS Price Unit Adiphenine Hydrochloride O LGC Standards N O MM1172.00 Adiphenine Hydrochloride 50-42-0 A 250mg HCl Pharmaceutical impurities and Adrenaline Tartrate OH H OH O OH primary reference standardsMM0614.00 2014 N OH Adrenaline Tartrate 51-42-3 A 500mg OH OH O OH OH H MM0614.02 L-Adrenaline 51-43-4 A 500mg OH N OH Imp. C (EP) as Hydrochloride: 1-(3,4-Di- O H OH MM0614.13 hydroxyphenyl)-2-(methylamino)ethanone 62-13-5 A 100mg N HCl Hydrochloride (Adrenalone Hydrochloride) OH (1R)-1-(3,4-Dihydroxyphenyl)-2- OH O S O MM0614.01 methylaminoethanesulphonic Acid H 78995-75-2 A 100mg OH N (Adrenaline -Sulphonate) OH Alanine NH2 MM0566.00 Alanine 56-41-7 A 500mg OH O Imp. A (Pharmeuropa): (2 S)-2-Aminobutanedioic Acid O NH 2 MM0567.00 OH (Aspartic Acid) 56-84-8 A 500mg OH O Albendazole O H MM0382.00 Albendazole N O 54965-21-8 A 500mg N H S N Imp. A (EP): 5-(Propylsulphanyl)-1H- H MM0382.01 N 80983-36-4 A 100mg NH2 benzimidazol-2-amine S N O H Imp. B (EP): Methyl [5-Propylsulphinyl)- N O MM0382.02 N 54029-12-8 A 100mg H 1H-benzimidazol-2-yl]carbamate S N O O H Imp.
  • Iodine-Containing Drugs

    Iodine-Containing Drugs

    Iodine-containing drugs Iodine-containing drugs (iodine) usually have an iodine content of >5mg/tablet or ml. The antiarrhythmic agent amiodarone, for example, contains 75 mg iodine/tablet, 10 ml betaisodona solution about 110 mg . - The administration of X-ray contrast media is another important reason for excessive iodine exposure. X-ray contrast media frequently contain > 100 mg iodine/ml. Contrast media contain almost exclusively organically bound iodine, but in vivo these compounds are partially deiodinated (deiodinase) (Mann et al. Eur J. Endocrinol 1994; 130 (5): 498). Assuming that water-soluble contrast media is eliminated within 10 to 14 days, enzymatic separation of iodine nevertheless leads to an offer of about 14 to 175 mg in the thyroid. Fat-soluble contrast media applied in cholecystograms have a much longer half time in the organism, and iodine can consequently be separated long. The table of Surks et al. (New Engl J Med 1995; 333: 1688) gives a survey of the most important iodine preparations applied in the USA. Iodine Content of Some Iodine Containing Medications and Radiographic Contrast Agents SUBSTANCE AMOUNT OF IODINE Expectorants Iophen 25 mg/ml Organidin (iodinated glycerol) 15 mg/tablet Par Glycerol 5 mg/ml R-Gen 6 mg/ml Iodides Potassium iodide (saturated solution) -25 mg/drop Pima syrup (potassium iodide) 255 mg/ml Lugol's solution (potassium iodide -7 mg/drop + iodine) Iodo-Niacin 115 mg/tablet Antiasthmatic drugs Mudrane 195 mg/tablet Elixophyllin-KI (theophylline) elixir 6.6 mg/ml © Merck KGaA 2002 Iophylline 2 mg/ml Antiarrhythmic drugs Amiodarone 75 mg/tablet Antiamebic drugs Iodoquinol 134 mg/tablet Topical antiseptic agents Poidone-iodine 10 mg/ml Clioquinol 12 mg/g Douches Povidone-iodine 10 mg/ml Radiographic contrast agents Iopanoic acid 333 mg/tablet Ipodate sodium 308 mg/tablet Intravenous preparations 140-380 mg/ml M.J.